Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Allogene Therapeutics, Inc.. (11/5/18). "Press Release: Allogene Therapeutics Announces November 2018 Investor Conference Schedule". South San Francisco, CA.

Region Region London, Greater London
  Country United Kingdom (GB)
Organisations Organisation Allogene Therapeutics Inc. (Nasdaq: ALLO)
  Organisation 2 Jefferies International Ltd.
  Group Leucadia (Group)
Product Product  Jefferies 2018 London Healthcare Conference
Index terms Index term Allogene Therapeutics–Leucadia: investor conference, 201811 supply service Allogene presents at Jefferies 2018 London Healthcare Conference
  Index term 2 Allogene Therapeutics–Piper Jaffray: investor conference, 201811 supply service Allogene presents at Piper Jaffray Healthcare Conference in NYC

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two investor conferences in November 2018.

Jefferies London Healthcare Conference
Wednesday, November 14, 2018
10:20 a.m. EST
London, U.K.

Piper Jaffray Healthcare Conference
Tuesday, November 27, 2018
1:30 p.m. EST
New York, NY

A live audio webcast of each event will be available on the Investors section of Allogene’s website, A replay of each webcast will be available on the website for approximately two weeks.

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.

AlloCAR T™ cell therapies are engineered from cells of healthy donors, which is intended to allow for creation of inventory for on demand use in patients. This approach is designed to eliminate the need to create personalized therapy from a patient’s own cells, simplify manufacturing, and reduce the time patients must wait for CAR T cell treatment. The Allogene portfolio includes rights to 16 pre-clinical CAR T cell therapy targets and UCART19, an AlloCAR T™ therapy candidate currently in Phase 1 sponsored by Servier for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). For more information, please visit, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form S-1 originally filed with the SEC on September 14, 2018. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326

Record changed: 2018-12-02


Picture [iito] Made Without Love 650x80px

More documents for Allogene Therapeutics Inc. (Nasdaq: ALLO)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top